Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine in high-risk neuroblastoma

Norgine United Kingdom United States of America Germany Spain Switzerland Netherlands Italy France Belgium Australia Austria

View original content:https://www.prnewswire.co.uk/news-releases/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-302343047.html